Market Trends– category –
-
Medtronic Launches Simplera Sync CGM Sensor in South Korea, Streamlining Glucose Management for MiniMed 780G Users
KBR South Korea Overview Medtronic has launched its Simplera Sync Sensor, a new continuous glucose monitoring (CGM) device, in South Korea for users of the MiniMed 780G automated insulin delivery (AID) system. This all-in-one disposable ... -
Compliance.ai Reports Over 11,000 New Regulatory Documents Added in Last 7 Days, With 50 Final Rules Taking Effect Soon
Compliance.ai USA Overview Compliance.ai announced the addition of 11,906 new proposed and final regulatory documents to its platform in the past seven days, reflecting a rapidly evolving regulatory landscape. The U.S. has recorded 1,558... -
U.S. NSF Fuels Regional Tech Hubs with $150M for Quantum, Bio, and Grid Modernization
Government News Release or University Announcement USA Overview The U.S. National Science Foundation (NSF) is investing $150 million in 12 new Regional Innovation Engines, initially providing $15 million over two years with potential exp... -
Canadian Government Designates Nanotechnology as R&D Priority, Offers Over 1500 Grant and Loan Programs
Canada.ca Canada Overview Canada's Business Benefits Finder lists over 1500 support programs, including grants, loans, and tax credits, with nanotechnology designated as a key research and development (R&D) focus area. These programs... -
China’s First Approved MSC Therapy, Ruibosheng, Launched at Fraction of Global Price, Receives Conditional Approval for Severe GVHD
BioInformant China Overview China's first approved mesenchymal stem cell (MSC) therapy, Ruibosheng, has been launched at a fraction of global pricing, having received conditional approval from the NMPA on January 2, 2025. Approved for st... -
Real-World Data Evaluates Incidence and Management of Cytokine Release Syndrome and Neurotoxicity Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel CAR-T Cell Therapy Across 87 U.S. Centers
PubMed (Center for International Blood and Marrow Transplant Research) USA Overview The Center for International Blood and Marrow Transplant Research (CIBMTR) conducted a real-world data analysis of 927 B-cell malignancy patients across ... -
ImmunoAct’s NexCAR19 Achieves 98% MRD Negativity in India with Significant Cost Reduction Compared to Western CAR-T Therapies
Citeline Scrip India Overview ImmunoAct's CAR-T cell therapy, NexCAR19 (talicabtagene autoleucel), achieved a 98% minimal residual disease (MRD) negativity rate in real-world Indian data, delivering comparable efficacy to Western CAR-T t... -
Advancements in Cell and Gene Therapy Manufacturing: Automation, Cost Reduction, and Scalability Revolutionize Patient Access
Bioprocessing Summit Europe International Overview The cell and gene therapy (CGT) manufacturing sector faces significant operational challenges, including high costs and scalability constraints, particularly due to raw material variabil... -
Capra Biosciences Boosts Domestic Manufacturing of Essential Medicines with Continued HHS Support, Strengthening Biopharmaceutical Supply Chain Resilience
BioSpace USA Overview Capra Biosciences announced plans to strengthen its domestic manufacturing capabilities for essential medicines with ongoing financial support from the U.S. Department of Health and Human Services (HHS). This initia... -
Fate Therapeutics’ iPSC-Derived CAR-T FT819 Shows Safety and Improved Skin Scores in Refractory Systemic Sclerosis Phase 1; Repligen Acquires BioLife Solutions for $1.5 Billion
DeciBio USA Overview July 2026 highlights in next-generation therapeutics include Fate Therapeutics' preliminary Phase 1 data for FT819, an iPSC-derived CD19-targeted CAR-T cell therapy for treatment-refractory systemic sclerosis, demons...
